258 related articles for article (PubMed ID: 25496649)
1. Inhibition of GPR30 by estriol prevents growth stimulation of triple-negative breast cancer cells by 17β-estradiol.
Girgert R; Emons G; Gründker C
BMC Cancer; 2014 Dec; 14():935. PubMed ID: 25496649
[TBL] [Abstract][Full Text] [Related]
2. 17β-estradiol-induced growth of triple-negative breast cancer cells is prevented by the reduction of GPER expression after treatment with gefitinib.
Girgert R; Emons G; Gründker C
Oncol Rep; 2017 Feb; 37(2):1212-1218. PubMed ID: 27959426
[TBL] [Abstract][Full Text] [Related]
3. Inactivation of GPR30 reduces growth of triple-negative breast cancer cells: possible application in targeted therapy.
Girgert R; Emons G; Gründker C
Breast Cancer Res Treat; 2012 Jul; 134(1):199-205. PubMed ID: 22290080
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of growth hormone receptor by Somavert reduces expression of GPER and prevents growth stimulation of triple-negative breast cancer by 17β-estradiol.
Girgert R; Emons G; Gründker C
Oncol Lett; 2018 Jun; 15(6):9559-9566. PubMed ID: 29805678
[TBL] [Abstract][Full Text] [Related]
5. GPER mediates enhanced cell viability and motility via non-genomic signaling induced by 17β-estradiol in triple-negative breast cancer cells.
Yu T; Liu M; Luo H; Wu C; Tang X; Tang S; Hu P; Yan Y; Wang Z; Tu G
J Steroid Biochem Mol Biol; 2014 Sep; 143():392-403. PubMed ID: 24874276
[TBL] [Abstract][Full Text] [Related]
6. G protein-coupled receptor 30 (GPR30) mediates gene expression changes and growth response to 17beta-estradiol and selective GPR30 ligand G-1 in ovarian cancer cells.
Albanito L; Madeo A; Lappano R; Vivacqua A; Rago V; Carpino A; Oprea TI; Prossnitz ER; Musti AM; Andò S; Maggiolini M
Cancer Res; 2007 Feb; 67(4):1859-66. PubMed ID: 17308128
[TBL] [Abstract][Full Text] [Related]
7. Estrogen action via the G protein-coupled receptor, GPR30: stimulation of adenylyl cyclase and cAMP-mediated attenuation of the epidermal growth factor receptor-to-MAPK signaling axis.
Filardo EJ; Quinn JA; Frackelton AR; Bland KI
Mol Endocrinol; 2002 Jan; 16(1):70-84. PubMed ID: 11773440
[TBL] [Abstract][Full Text] [Related]
8. Focal adhesion kinase (FAK) activation by estrogens involves GPER in triple-negative breast cancer cells.
Rigiracciolo DC; Santolla MF; Lappano R; Vivacqua A; Cirillo F; Galli GR; Talia M; Muglia L; Pellegrino M; Nohata N; Di Martino MT; Maggiolini M
J Exp Clin Cancer Res; 2019 Feb; 38(1):58. PubMed ID: 30728047
[TBL] [Abstract][Full Text] [Related]
9. Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF.
Filardo EJ; Quinn JA; Bland KI; Frackelton AR
Mol Endocrinol; 2000 Oct; 14(10):1649-60. PubMed ID: 11043579
[TBL] [Abstract][Full Text] [Related]
10. The G protein-coupled receptor GPR30 mediates c-fos up-regulation by 17beta-estradiol and phytoestrogens in breast cancer cells.
Maggiolini M; Vivacqua A; Fasanella G; Recchia AG; Sisci D; Pezzi V; Montanaro D; Musti AM; Picard D; Andò S
J Biol Chem; 2004 Jun; 279(26):27008-16. PubMed ID: 15090535
[TBL] [Abstract][Full Text] [Related]
11. Interaction Between CCL18 and GPR30 Differs from the Interaction Between Estradiol and GPR30.
Schmidt-Wolf R; Zissel G
Anticancer Res; 2020 Jun; 40(6):3097-3108. PubMed ID: 32487604
[TBL] [Abstract][Full Text] [Related]
12. 17beta-estradiol, genistein, and 4-hydroxytamoxifen induce the proliferation of thyroid cancer cells through the g protein-coupled receptor GPR30.
Vivacqua A; Bonofiglio D; Albanito L; Madeo A; Rago V; Carpino A; Musti AM; Picard D; Andò S; Maggiolini M
Mol Pharmacol; 2006 Oct; 70(4):1414-23. PubMed ID: 16835357
[TBL] [Abstract][Full Text] [Related]
13. The G protein-coupled receptor GPR30 inhibits human urothelial cell proliferation.
Teng J; Wang ZY; Prossnitz ER; Bjorling DE
Endocrinology; 2008 Aug; 149(8):4024-34. PubMed ID: 18467434
[TBL] [Abstract][Full Text] [Related]
14. The G protein-coupled receptor GPR30 inhibits proliferation of estrogen receptor-positive breast cancer cells.
Ariazi EA; Brailoiu E; Yerrum S; Shupp HA; Slifker MJ; Cunliffe HE; Black MA; Donato AL; Arterburn JB; Oprea TI; Prossnitz ER; Dun NJ; Jordan VC
Cancer Res; 2010 Feb; 70(3):1184-94. PubMed ID: 20086172
[TBL] [Abstract][Full Text] [Related]
15. Nuclear alternate estrogen receptor GPR30 mediates 17beta-estradiol-induced gene expression and migration in breast cancer-associated fibroblasts.
Madeo A; Maggiolini M
Cancer Res; 2010 Jul; 70(14):6036-46. PubMed ID: 20551055
[TBL] [Abstract][Full Text] [Related]
16. 17β-Estradiol on the Expression of G-Protein Coupled Estrogen Receptor (GPER/GPR30) Mitophagy, and the PI3K/Akt Signaling Pathway in ATDC5 Chondrocytes In Vitro.
Fan DX; Yang XH; Li YN; Guo L
Med Sci Monit; 2018 Apr; 24():1936-1947. PubMed ID: 29608013
[TBL] [Abstract][Full Text] [Related]
17. The G protein-coupled receptor GPR30 mediates the proliferative effects induced by 17beta-estradiol and hydroxytamoxifen in endometrial cancer cells.
Vivacqua A; Bonofiglio D; Recchia AG; Musti AM; Picard D; Andò S; Maggiolini M
Mol Endocrinol; 2006 Mar; 20(3):631-46. PubMed ID: 16239258
[TBL] [Abstract][Full Text] [Related]
18. Assessment of cell line competence for studies of pharmacological GPR30 modulation.
Sousa C; Ribeiro M; Rufino AT; Leitão AJ; Mendes AF
J Recept Signal Transduct Res; 2017 Apr; 37(2):181-188. PubMed ID: 27401115
[TBL] [Abstract][Full Text] [Related]
19. The novel estrogen receptor, G protein-coupled receptor 30, mediates the proliferative effects induced by 17beta-estradiol on mouse spermatogonial GC-1 cell line.
Sirianni R; Chimento A; Ruggiero C; De Luca A; Lappano R; Andò S; Maggiolini M; Pezzi V
Endocrinology; 2008 Oct; 149(10):5043-51. PubMed ID: 18566133
[TBL] [Abstract][Full Text] [Related]
20. Epidermal growth factor induces G protein-coupled receptor 30 expression in estrogen receptor-negative breast cancer cells.
Albanito L; Sisci D; Aquila S; Brunelli E; Vivacqua A; Madeo A; Lappano R; Pandey DP; Picard D; Mauro L; Andò S; Maggiolini M
Endocrinology; 2008 Aug; 149(8):3799-808. PubMed ID: 18467441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
